Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience-Reference-Cited by-同舟云学术

Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience

Published:2021-03 Issue: Volume:153 Page:150-157
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Eichhorn Florian^ORCID,Klotz Laura V.,Kriegsmann Mark^ORCID,Bischoff Helge^ORCID,Schneider Marc A.^ORCID,Muley Thomas^ORCID,Kriegsmann Katharina,Haberkorn Uwe,Heussel Claus Peter,Savai Rajkumar,Zoernig Inka,Jaeger Dirk,Thomas Michael^ORCID,Hoffmann Hans,Winter Hauke,Eichhorn Martin E.^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference41 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018

2. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer;Asamura;J. Thorac. Oncol.,2015

3. Non-small-cell lung cancer;Goldstraw;Lancet,2011

4. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer;Arriagada;J. Clin. Oncol.,2010

5. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anatomische Lungenresektion nach neoadjuvanter Chemo-Immuntherapie: technische Aspekte und klinische Fallbeispiele;Zentralblatt für Chirurgie - Zeitschrift für Allgemeine, Viszeral-, Thorax- und Gefäßchirurgie;2024-08

2. Prognostic implication of methylation-based circulating tumor DNA detection prior to surgery in stage I non-small cell lung cancer;Cancer Letters;2024-07

3. Molecular Markers, Immune Therapy, and Non-Small Cell Lung Cancer—State-of-the-Art Review for Surgeons;Journal of Laparoendoscopic & Advanced Surgical Techniques;2024-06-20

4. A current comprehensive role of immune-checkpoint inhibitors in resectable non-small cell lung cancer: A narrative review;Journal of Oncology Pharmacy Practice;2024-06-11

5. Efficacy and safety of different cycles of neoadjuvant immunotherapy in resectable non-small cell lung cancer: A systematic review and meta-analysis;Heliyon;2024-06